Abstract
Chronic sustained stimulation of β-adrenoceptor is closely related to cardiac fibrosis which is bad for cardiac function. Growing evidence showed that the high prevalence of β1-adrenoceptor autoantibody (β1-AA) in the sera of patients with various types of cardiovascular diseases decreased cardiac function. In the current study, we demonstrated that β1-AA impaired the cardiac function evaluated by echocardiography and that β1-AA triggered cardiac fibrosis in terms of increased expression of α-smooth muscle actin as the marker of myofibroblast and collagen deposition in a passive β1-AA immunized mice model during 16 weeks. Further, we showed that β1-AA activated β1-AR/cAMP/PKA pathway and promoted proliferation in primary cardiac fibroblasts through specific binding to β1-AR but not to β2-AR. Moreover, β1-AA was also likely to promote proliferation in cardiac fibroblasts through activating p38MAPK and ERK1/2 as p38MAPK inhibitor SB203580 and ERK1/2 inhibitor PD98059 partially reversed the proliferative effect. The persistent activating signalling of PKA and P38MAPK in 1 h induced by β1-AA was associated with lacking agonist-induced desensitization phenomena. The conditioned medium from β1-AA-stimulated cardiac fibroblasts induced cardiomyocyte apoptosis, which indicated that β1-AA changed the secretion of cardiac fibroblasts contributing to cardiac injury. These findings will contribute to our understanding of the pathological mechanisms of β1-AA.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Actins / genetics
-
Actins / immunology
-
Amino Acid Sequence
-
Animals
-
Animals, Newborn
-
Autoantibodies / administration & dosage
-
Autoantibodies / biosynthesis
-
Cell Line
-
Cell Proliferation / drug effects
-
Echocardiography
-
Endomyocardial Fibrosis / etiology
-
Endomyocardial Fibrosis / genetics
-
Endomyocardial Fibrosis / immunology*
-
Endomyocardial Fibrosis / pathology
-
Fibroblasts / drug effects
-
Fibroblasts / immunology*
-
Fibroblasts / pathology
-
Flavonoids / pharmacology
-
Gene Expression Regulation
-
Imidazoles / pharmacology
-
Immunization, Passive
-
Mice
-
Mice, Inbred BALB C
-
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
-
Mitogen-Activated Protein Kinase 1 / genetics
-
Mitogen-Activated Protein Kinase 1 / immunology
-
Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
-
Mitogen-Activated Protein Kinase 3 / genetics
-
Mitogen-Activated Protein Kinase 3 / immunology
-
Myocardium / immunology*
-
Myocardium / pathology
-
Myocytes, Cardiac / drug effects
-
Myocytes, Cardiac / immunology*
-
Myocytes, Cardiac / pathology
-
Primary Cell Culture
-
Pyridines / pharmacology
-
Rats
-
Receptors, Adrenergic, beta-1 / genetics*
-
Receptors, Adrenergic, beta-1 / immunology
-
Signal Transduction
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases / genetics
-
p38 Mitogen-Activated Protein Kinases / immunology
Substances
-
Actins
-
Autoantibodies
-
Flavonoids
-
Imidazoles
-
Pyridines
-
Receptors, Adrenergic, beta-1
-
smooth muscle actin, rat
-
Mapk1 protein, mouse
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
p38 Mitogen-Activated Protein Kinases
-
SB 203580
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one